Thoughts on the research of African swine fever live-attenuated vaccines

被引:1
|
作者
Chu, Xuefei [1 ]
Ge, Shengqiang [2 ,3 ,4 ]
Zuo, Yuanyuan [2 ]
Cui, Jin [2 ]
Sha, Zhou [2 ]
Han, Naijun [2 ]
Wu, Bingrong [1 ]
Ni, Bo [2 ]
Zhang, Hui [2 ]
Lv, Yan [2 ]
Wang, Zhiliang [2 ]
Xiao, Yihong [1 ]
机构
[1] Shandong Agr Univ, Coll Anim Sci & Technol, 61 Daizong St, Tai An 271018, Shandong Provin, Peoples R China
[2] China Anim Hlth & Epidemiol Ctr, 369 Nanjing Rd, Qingdao 266032, Peoples R China
[3] Qingdao Key Lab Modern Bioengn & Anim Dis Res, Qingdao 266032, Peoples R China
[4] Minist Agr & Rural Affairs, Key Lab Anim Biosafety Risk Warning Prevent & Cont, Qingdao 266032, Shandong, Peoples R China
关键词
Live attenuated vaccine; Gene-deficient vaccine strain; Immunization; Challenge protection; Safty; ISOLATE HARBORING DELETIONS; VIRULENCE-ASSOCIATED GENE; GEORGIA ISOLATE; PORCINE MACROPHAGES; DOMESTIC PIGS; VIRUS; PROTECTION; INFECTION; 9GL; EXPRESSION;
D O I
10.1016/j.vaccine.2024.06.020
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
African swine fever (ASF) is a contagious and fatal disease caused by the African swine fever virus (ASFV), which can infect pigs of all breeds and ages. Most infected pigs have poor prognosis, leading to substantial economic losses for the global pig industry. Therefore, it is imperative to develop a safe and efficient commercial vaccine against ASF. The development of ASF vaccine can be traced back to 1960. However, because of its large genome, numerous encoded proteins, and complex virus particle structure, currently, no effective commercial vaccine is available. Several strategies have been applied in vaccine design, some of which are potential candidates for vaccine development. This review provides a comprehensive analysis on the safety and effectiveness, suboptimal immunization effects at high doses, absence of standardized evaluation criteria, notable variations among strains of the same genotype, and the substantial impact of animal health on the protective efficacy against viral challenge. All the information will be helpful to the ASF vaccine development.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Perspectives of Next-Generation Live-Attenuated Rift Valley Fever Vaccines for Animal and Human Use
    Schreur, Paul Wichgers J.
    Bird, Brian H.
    Ikegami, Tetsuro
    Bermudez-Mendez, Erick
    Kortekaas, Jeroen
    VACCINES, 2023, 11 (03)
  • [32] Rational Design of Live-Attenuated Vaccines against GenomeReduced Pathogens
    Nishikawa, Sayaka
    Ogawa, Yohsuke
    Shiraiwa, Kazumasa
    Nozawa, Rieko
    Nakayama, Momoko
    Eguchi, Masahiro
    Shimoji, Yoshihiro
    MICROBIOLOGY SPECTRUM, 2022, 10 (06):
  • [33] Development of Live-Attenuated Arenavirus Vaccines Based on Codon Deoptimization
    Cheng, Benson Yee Hin
    Ortiz-Riano, Emilio
    Nogales, Aitor
    de la Torre, Juan Carlos
    Martinez-Sobrido, Luis
    JOURNAL OF VIROLOGY, 2015, 89 (07) : 3523 - 3533
  • [34] Live-attenuated HIV vaccines: How safe is safe enough?
    Michael Murphey-Corb
    Nature Medicine, 1997, 3 : 17 - 18
  • [35] Viral Live-Attenuated Vaccines (LAVs): Past and Future Directions
    Tang, Yan-Dong
    Li, Yuming
    Cai, Xue-Hui
    Yin, Xin
    ADVANCED SCIENCE, 2025, 12 (03)
  • [36] Vaccines for African swine fever: an update
    Zhang, Hongliang
    Zhao, Saisai
    Zhang, Haojie
    Qin, Zhihua
    Shan, Hu
    Cai, Xiulei
    FRONTIERS IN MICROBIOLOGY, 2023, 14
  • [37] Live-attenuated HIV vaccines: How safe is safe enough?
    MurpheyCorb, M
    NATURE MEDICINE, 1997, 3 (01) : 17 - 18
  • [38] Live-Attenuated Oral Vaccines to Reduce Campylobacter Colonization in Poultry
    Jeon, Byeonghwa
    Saisom, Tunchanok
    Sasipreeyajan, Jiroj
    Luangtongkum, Taradon
    VACCINES, 2022, 10 (05)
  • [39] General Molecular Strategy for Development of Arenavirus Live-Attenuated Vaccines
    Iwasaki, Masaharu
    Ngo, Nhi
    Cubitt, Beatrice
    Teijaro, John R.
    de la Torre, Juan C.
    JOURNAL OF VIROLOGY, 2015, 89 (23) : 12166 - 12177
  • [40] DNA-launched live-attenuated vaccines for biodefense applications
    Pushko, Peter
    Lukashevich, Igor S.
    Weaver, Scott C.
    Tretyakova, Irina
    EXPERT REVIEW OF VACCINES, 2016, 15 (09) : 1223 - 1234